Medtronic Received FDA Approval for Smallest-Diameter, Lumenless Defibrillation Lead, the Omniasecure™ Lead and Published Investigational Clinical Study Results, Offering New Therapy Option for Heart Rhythm Disorders
On April 25, 2025, Medtronic plc., a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for its OmniaSecure™ defibrillation lead. This next-generation lead is designed for precise, catheter-based placement in the right ventricle and builds on the proven performance of the SelectSecure™ Model 3830 pacing lead platform.
At just 4.7 French (1.6mm), OmniaSecure is the smallest defibrillation lead avai...